Alligator Announces First Patient Dosed in Investigator-Initiated Study of Intratumoral Mitazalimab in Early-Stage Breast Cancer

Alligator Announces First Patient Dosed in Investigator-Initiated Study of Intratumoral Mitazalimab in Early-Stage Breast Cancer

LUND, SE / ACCESS Newswire / July 2, 2026 / Alligator Bioscience (STO:ATORX)First patient dosed in an

Alligator highlights first patient dosed in trial of mitazalimab in breast cancer - BioTuesdays

Alligator Bioscience (STO: ATORX) has announced that the first patient has been dosed in an investigator-led trial evaluating the intratumoral administration of mitazalimab, the company’s lead CD40 agonist, in patients with early-stage breast cancer. According to Alligator, the study will evaluate mitazalimab given as a single intratumoral dose, either alone or in combination with a single intratumoral dose of the PD-1 inhibitor nivolumab, prior…